George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10,678.00
Bid: 10,688.00
Ask: 10,690.00
Change: -64.00 (-0.60%)
Spread: 2.00 (0.019%)
Open: 10,756.00
High: 10,780.00
Low: 10,674.00
Prev. Close: 10,742.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Brilinta met primary endpoint in stroke trial

27 Jan 2020 07:00

RNS Number : 9331A
AstraZeneca PLC
27 January 2020
 

27 January 2020 07:00 GMT

 

Brilinta met primary endpoint in Phase III THALES trial in stroke

 

Brilinta reduced the risk of the composite of stroke and deathafter an acute ischaemic stroke or transient ischaemic attack

 

High-level results from the Phase III THALES trial showed AstraZeneca's Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone.

 

THALES was conducted in over 11,000 patients who had a minor acute ischaemic stroke or high-risk transient ischaemic attack (TIA) in the 24 hours prior to treatment initiation. The preliminary safety findings in the THALES trial were consistent with the known profile of Brilinta, with an increased bleeding rate in the treatment arm.

 

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: "Results of the Phase III THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack. We look forward to sharing the detailed results with health authorities."

 

Dr. Clay Johnston, lead investigator for the THALES trial and Dean of the Dell Medical School at The University of Texas at Austin, US, said: "The risk of having a subsequent stroke is highest in the first few days and weeks after a minor acute ischaemic stroke or high-risk transient ischaemic attack. While an expected increase in bleeding was observed, the findings from THALES showed that Brilinta, in combination with aspirin, reduced the risk of potentially devastating events in this crucial time."

 

The full THALES trial results will be presented at a forthcoming medical meeting.

 

Brilinta is approved in more than 110 countries for the treatment of acute coronary syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular (CV) events among high-risk patients who have experienced a heart attack.

 

Stroke

Stroke is the second leading cause of death worldwide, with 6.2 million stroke-related deaths in 2017, from which 2.7 million were due to ischaemic stroke.1 Patients who experience an acute ischaemic stroke or TIA are at high risk of developing subsequent ischaemic events, with particularly high risk within 30 days after the initial event and the highest risk period being the first 24 hours after the initial event.2

 

THALES

THALES is an AstraZeneca-sponsored, randomised, placebo-controlled, double-blinded, international, multicentre, event-driven trial involving more than 11,000 patients to test the hypothesis whether Brilinta and aspirin is superior to aspirin alone in preventing the composite of stroke and death in patients with minor acute ischaemic stroke or high-risk TIA. Patients were randomised within 24 hours of onset of acute ischaemic stroke or high-risk TIA symptoms and followed-up for 30 days of treatment. Trial treatments were Brilinta 180mg loading dose on day 1 as soon as possible after randomisation, followed by 90mg twice daily on days 2-30, or matching placebo. All patients received open-label aspirin 300-325mg on day 1, followed by 75-100mg once daily on days 2-30. The primary efficacy outcome was the time to the composite endpoint of stroke and death at 30 days. The primary safety outcome is time to first severe bleeding event according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition. Patients were followed for an additional 30 days on standard of care.

 

Brilinta

Brilinta is an oral, reversible, direct-acting P2Y12 receptor antagonist that works by inhibiting platelet activation. Brilinta, together with aspirin, has been shown to significantly reduce the risk of major adverse CV events (myocardial infarction, stroke or CV death), in patients with ACS or a history of myocardial infarction (MI).

 

Brilinta, co-administered with aspirin, is indicated for the prevention of atherothrombotic events in adult patients with ACS, or for patients with a history of MI and a high risk of developing an atherothrombotic event.

 

AstraZeneca in CVRM

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca's three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling comorbidities. The Company's ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Media Relations

Gonzalo Viña

+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Angela Fiorin

BioPharmaceuticals

+44 1223 344 690

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677

Investor Relations

Thomas Kudsk Larsen

+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharmaceuticals

(Cardiovascular, Metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals (Renal) Environmental, Social and Governance

+44 203 749 5716

Josie Afolabi

BioPharmaceuticals (Respiratory)

 

+44 203 749 5631

Tom Waldron

Other medicines

+44 7385 033 717

Craig Marks

Finance

Fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access

Retail investors

+44 203 749 5824

US toll-free

+1 866 381 72 77

 

References

1. Roth GA et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018; 392(10159):1736-88.

2. Khanevski AN, et al. Thirty-day recurrence after ischemic stroke or TIA. Brain Behav 2018; 8(10):e01108.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBFMBTMTBTTBM
Date   Source Headline
25th Mar 20247:00 amRNSUltomiris approved in the US for NMOSD
19th Mar 20247:00 amRNSAstraZeneca to acquire Fusion
14th Mar 20247:00 amRNSAstraZeneca to acquire Amolyt
12th Mar 202411:00 amRNSDirector/PDMR Shareholding
7th Mar 202411:00 amRNSNotice of AGM
6th Mar 20243:05 pmRNSDirector/PDMR Shareholding
6th Mar 20243:00 pmRNSDirector/PDMR Shareholding
4th Mar 20247:00 amRNSEMA validates Dato-DXd MAAs for NSQ NSCLC and BC
1st Mar 20243:00 pmRNSTotal Voting Rights
26th Feb 20247:00 amRNSVoydeya recommended for EU approval
22nd Feb 20241:15 pmRNSAcquisition of Gracell completed
22nd Feb 202411:00 amRNSDirector/PDMR Shareholding
22nd Feb 20247:00 amRNSAstraZeneca prices a $5bn bond offering
21st Feb 20247:00 amRNSFiling of Form 20-F with SEC
20th Feb 202411:00 amRNSAnnual Financial Report
19th Feb 20243:00 pmRNSAstraZeneca completes acquisition of Icosavax
19th Feb 20247:10 amRNSTagrisso plus chemo approved in US for lung cancer
19th Feb 20247:05 amRNSFDA accepts Dato-DXd BLA for nonsquamous NSCLC
19th Feb 20247:00 amRNSTagrisso improved PFS in Stage III lung cancer
8th Feb 20247:00 amRNSFinal Results
1st Feb 20243:00 pmRNSTotal Voting Rights
2nd Jan 20243:00 pmRNSTotal Voting Rights
27th Dec 20237:00 amRNSAstraZeneca acquires Gracell
22nd Dec 20237:00 amRNSWainua (eplontersen) granted first US FDA approval
14th Dec 20233:00 pmRNSDirector/PDMR Shareholding
12th Dec 20237:05 amRNSAstraZeneca to acquire Icosavax
1st Dec 20233:05 pmRNSBlock listing Interim Review
1st Dec 20233:00 pmRNSTotal Voting Rights
1st Dec 20237:00 amRNSDiscontinuation of two CRYSTALIZE evidence trials
23rd Nov 20233:00 pmRNSDirector/PDMR Shareholding
17th Nov 20237:00 amRNSTruqap approved in US for HR+ breast cancer
14th Nov 20237:05 amRNSUpdate on PACIFIC-2 Phase III trial for Imfinzi
9th Nov 20233:00 pmRNSDirector Declaration
9th Nov 20237:10 amRNSImfinzi combination improves PFS in liver cancer
9th Nov 20237:05 amRNSAgreement with Eccogene for clinical stage GLP-1RA
9th Nov 20237:00 amRNS9M and Q3 2023 results
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSAstraZeneca cell & gene therapy deal w/ Cellectis
3rd Oct 20237:00 amRNSAstraZeneca settles Nexium liability litigations
2nd Oct 20233:00 pmRNSTotal Voting Rights
22nd Sep 20237:00 amRNSDato-DXd improved PFS in breast cancer
20th Sep 20237:00 amRNSAlexion completes Pfizer gene therapy agreement
15th Sep 20233:00 pmRNSEnhertu recommended in EU for HER2-mutant NSCLC
11th Sep 20234:00 pmRNSFasenra Phase III EGPA trial met primary endpoint
6th Sep 20237:00 amRNSUpdate on US review of Ultomiris for NMOSD
1st Sep 20233:00 pmRNSTotal Voting Rights
1st Aug 20233:00 pmRNSTotal Voting Rights
28th Jul 20237:05 amRNSAlexion enters gene therapy agreement with Pfizer
28th Jul 20237:00 amRNSHalf-year Report
17th Jul 20236:10 pmRNSBeyfortus approved in US for infant RSV prevention

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.